

Immunotherapy for the Treatment of Microsatellite Instability – High Cancers

Haider Mahdi, MD, MPH

Gynecologic Oncology

Cleveland Clinic









Society for Immunotherapy of Cancer



- Consulting Fees: Tesaoro for Niraparib
- Research Grant: Puma Biotechnology
- Area of research interest especially MSI-H and ovarian cancers
- I will be discussing non-FDA approved indications during my presentation.





DNA Mismatch Repair/Microsatellite Instability

- The presence of microsatellite instability (MSI) represents phenotypic evidence of mismatch repair (MMR) dysfunction.
- MMR dysfunction can be caused by mutations in genes that code for MMR proteins (MLH1, MSH2, MSH6, PMS2)
- Diagnosed by IHC, PCR or NGS
- Mutations in MMR proteins can result from:
 - Hereditary causes (Lynch syndrome)
 - Somatic mutations
 - Silencing through promoter methylation






Microsatellite Instability


Rate (%)

ŝ

Objective


- Highly immunogenic tumors
- Increased somatic mutation and mutational burden
 - High NeoAgs burden
- Particularly sensitive to immunotherapy, PD1/PDL1 inhibitors
 - Rapid expansion of neoantigen-specific T cell clones that are reactive to tumor neoantigens





© 2019–2020 Society for Immunotherapy of Cancer

MSI-H/dMMR tumors have high TMB





(sitc)


ADVANCES IN 🏑

Society for Immunotherapy of Cancer



Many tumors are MSI-high or MMRdeficient

- Endometrial cancer (30%)
- Colorectal/gastric cancer (20%, up to 5% of metastatic patients)
- Genitourinary, breast, thyroid, others (<5%)
- Also share histopathological characteristics, like immune cell infiltration, medullary histology, poorly differentiated
- Prognosis with MSI-H appears to be stage-specific
 - Localized, surgically-resected is favorable
 - Metastatic = not favorable
 - Trend toward lower response to chemotherapy stage in one study in MSI-H endometrial cance
 - Epigenetic MMR defect
 - 48% vs. 3.4% in one study





FDA-approved immunotherapies for MSI-high populations


Drug	Approved	Indication	Dose
Pembrolizumab	2017	Adult/pediatric patients with unresectable/metastatic MSI-H or dMMR solid tumors with progression on other treatment MSI-H or dMMR colorectal cancer with progression after 5FU, oxaplatin, and irinotecan	Adults: 200 mg Q3W Pediatric: 2 mg/kg (up to 200 mg) Q3W
Nivolumab	2017	Patients >12 yr with MSI-H/dMMR metastatic CRC with progression after fluoropyrimidine, oxaplatin, and irinotecan	≥40 kg: 240 mg Q2W or 480 mg Q4W <40 kg: 3 mg/kg Q2W
Ipilimumab + nivolumab	2018	Patients >12 yr with MSI-H/dMMR metastatic CRC with progression after 5FU, oxaplatin, and irinotecan	≥40 kg: 3 mg/kg nivolumab + 1 mg/kg ipilimumab Q3W for 4 doses, Then nivolumab 240 mg Q2W or 480 mg Q4W






Clinical Data – pembrolizumab studies

- KEYNOTE-016: CRC only
 - no CR in MMR-proficient, 40% in dMMR
- KEYNOTE-164 and 158
 - ORR:
 - 27.9% for MSI-H CRC
 - 37.7% for MSI-H non-CRC
 - At 6 months OS:
 - 87% CRC
 - 73% non-CRC









• NCT01876511

- 12 cancer types with dMMR
- ORR: 53%
- CR: 21%



Le, Science 2017. © 2019–2020 Society for Immunotherapy of Cancer



Table 23: MSI-H Trials

Study	Design and Patient Population	Number of patients	MSI-H/dMMR testing	Dose	Prior therapy
KEYNOTE-016 NCT01876511	 prospective, investigator- initiated 6 sites patients with CRC and other tumors 	28 CRC 30 non-CRC	local PCR or IHC	10 mg/kg every 2 weeks	CRC: ≥ 2 prior regimens Non-CRC: ≥1 prior regimen
KEYNOTE-164 NCT02460198	prospective international multi- center CRC	61	local PCR or IHC	200 mg every 3 weeks	Prior fluoropyrimidine, oxaliplatin, and irinotecan +/- anti- VEGF/EGFR mAb
KEYNOTE-012 NCT01848834	 retrospectively identified patients with PD-L1-positive gastric, bladder, or triple- negative breast cancer 	6	central PCR	10 mg/kg every 2 weeks	≥1 prior regimen
KEYNOTE-028 NCT02054806	 retrospectively identified patients with PD-L1-positive esophageal, biliary, breast, endometrial, or CRC 	5	central PCR	10 mg/kg every 2 weeks	≥1 prior regimen
KEYNOTE-158 NCT02628067	 prospective international multi- center enrollment of patients with MSI-H/dMMR non-CRC retrospectively identified patients who were enrolled in specific rare tumor non-CRC cohorts 	19	local PCR or IHC (central PCR for patients in rare tumor non-CRC cohorts)	200 mg every 3 weeks	≥1 prior regimen
Total		149			

Table 24: Efficacy Results for Patients with MSI-H/dMMR Cancer

Endpoint	n=149
Objective response rate	
ORR (95% CI)	39.6% (31.7, 47.9)
Complete response rate	7.4
Partial response rate	32.2
Response duration	
Median in months (range)	NR (1.6+, 22.7+)
% with duration ≥6 months	78%


NR = not reached

CRC = colorectal cancer





CheckMate 142




- Median follow-up in the combination therapy cohort (N = 119) was 13.4 months (range, 9–25)^c
- Results of the monotherapy cohort (N = 74) with a similar median follow-up of 13.4 months (range, 10–32) are also presented^{1,c}





Clinical Data – CheckMate 142 Nivolumab monotherapy



- mCRC with MSI-H, progressed after ≥1 therapy
- Nivolumab 3 mg/kg Q2W
- At 12 months: 31% ORR
- 68.9% disease control >12 weeks
- Median DOR not reached







Clinical Data – CheckMate 142

Nivolumab + Ipilimumab

- MSI-H/dMMR mCRC
- Nivolumab 3mg/kg + ipilimumab 1 mg/kg Q3W (4 doses), then nivolumab 3 mg/kg Q2W
- At 13.4 months: 55% ORR
- PFS: 76% (9 months); 71% (12 months)












First Line metastatic MSI-H CRC

Nivo + Ipi: First Line MSI-H CRC



Heinz-Josef Lenz, ESMO 2018





ORR 60%, CBR 84% with durable deep responses

Response and Disease Control

Investigator-assessed	NIVO3 (Q2W) + IPI1 (Q6W) N = 45
ORRª, n (%) [95% CI]	27 (60) [44.3–74.3]
Best overall response, n (%)*	
CR	3 (7)
PR	24 (53)
SD	11 (24)
PD	6 (13)
Not determined	1 (2)
DCR ^b , n (%)	38 (84)
[95% CI]	[70.5–93.5]

- Responses were observed regardless of tumor PD-L1 expression, BRAF or KRAS mutation status, or diagnosis of Lynch syndrome
 - The ORR and DCR in patients with a BRAF mutation (n = 17) were 71% and 88%, respectively


*Percentages may not add up to 100% because of rounding

*Patients with CR or PR divided by the number of treated patients; *Patients with a CR, PR, or SD for ≥12 weeks divided by the number of treated patients





>80% of patients had decreased Tumor burden and benefit from therapy



84% of patients had a reduction in tumor burden from baseline

Heinz-Josef Lenz, ESMO 2018




We also have a set of the set of

*Confirmed response per investigator assessment



Durable response with mDoR was not reached

Characterization of Response



 Median time to response was 2.6 months (range, 1.2–13.8 months)

- Responses were durable:
 - Median DOR was not reached
 - 82% of responders had ongoing responses at data cutoff
 - 74% of responders have already had responses lasting ≥6 months
 - Most responders (96%) were alive at data cutoff

Heinz-Josef Lenz, ESMO 2018





In development for MSI-high

- Other tissue-agnostic markers:
 - Microbiome
 - POLE mutation
 - Mutational signatures beyond TMB
 - GEP immune signature (IFN-g signature)





- Loss of β 2 Microglobulin, a critical component of the antigen presentation machinery and MHC class I expression.
 - Gurjao C, Liu D, Hofree M, et al. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair Deficient Colorectal Cancer. Cancer Immunol Res. 2019 Jun 19. pii: canimm.0683.2018. doi: 10.1158/2326-6066.CIR-18-0683. [Epub ahead of print]
- Other mechanisms are similar to causes of resistance to ICI in any cancer type





Immunotherapy for the Treatment of Breast & Gynecologic Cancers Haider Mahdi, MD, MPH Gynecologic Oncology Cleveland Clinic





Current approvals

Drug	Approved	Indication	Dose
Atezolizumab + nab-paclitaxel	2019	Advanced/Metastatic TNBC with PD-L1 ≥1%	840 mg atezolizumab + 100 mg/m² nab- paclitaxel
Pembrolizumab	2017	MSI-H/dMMR advanced cancer with progression on previous treatment (includes especially endometrial)	200 mg Q3W
Pembrolizumab	2018	Recurrent/metastatic cervical cancer with PD-L1 (CPS ≥1) and progression on previous therapy	200 mg Q3W






Clinical Data – IMpassion130 PD-L1+ TNBC

Patients with metastatic or inoperable, locally advanced TNBC without prior therapy for advanced TNBC^a

Stratification factors:


- Prior (curative setting) taxane use (yes vs no)
- · Liver metastases (yes vs no)
- PD-L1 IC status (positive [≥ 1%] vs negative [< 1%])^c



- Co-primary endpoints in ITT and PD-L1 IC+: PFS and OS^d
- Pre-specified hierarchical testing of OS in ITT and, if significant, in PD-L1 IC+ patients
- In both treatment arms, 41% of patients were PD-L1 IC+



Clinical Data – IMpassion130 PD-L1+ TNBC




sitc



Cervical Cancer Clinical Data – KEYNOTE-158

- 82/98 were PD-L1(+)
- @10 months: ORR 14.6% (all in PD-L1(+) patients)



 mOS: 9.4 mo in total population; 11.0 mo in PD-L1(+)





Future Directions






In development: Breast cancer immunotherapy

NCT031998851st line HER2+ metastatic breast cancer• Pertuzumab + trastuzumab + paclitaxel + atezolizumab • Pertuzumab + trastuzumab + paclitaxel + placeboRecruitingKEYNOTE-756Neoadjuvant ER+/HER2- breast cancer• Pembrolizumab + chemo → pembrolizumab + endocrine therapy • Placebo + chemo → placebo + endocrine therapyPlannedNCT03804944 /CBCVPostmenopausal ER+/HER2- newly diagnosed breast cancer• Hypofractionated RT • Hypofractionated RT + pembrolizumab • Hypofractionated RT + Ftl-3 ligand • Hypofractionated RT + Ftl-3 ligand + pembrolizumabPlanned	Trial	Population	Arms	Status
ER+/HER2- breast cancerendocrine therapy Placebo + chemo → placebo + endocrine therapyNCT03804944 /CBCVPostmenopausal ER+/HER2- newly diagnosed breast cancer• Hypofractionated RT • Hypofractionated RT + pembrolizumab • Hypofractionated RT + Ftl-3 ligand • Hypofractionated RT + Ftl-3 ligand +Planned	NCT03199885	metastatic breast	atezolizumab	Recruiting
/CBCVER+/HER2- newly diagnosed breast cancerHypofractionated RT + pembrolizumab • Hypofractionated RT + Ftl-3 ligand • Hypofractionated RT + Ftl-3 ligand +	KEYNOTE-756	ER+/HER2- breast	endocrine therapy	Recruiting
		ER+/HER2- newly diagnosed breast	 Hypofractionated RT + pembrolizumab Hypofractionated RT + Ftl-3 ligand 	Planned





In development: Therapeutic strategies in ovarian cancer







JAVELIN Ovarian 100

Randomized Phase 3 Study (NCT02718417)



Dec 21, 2018: Planned interim analysis did not support the study's initial hypothesis, and therefore a decision was made to terminate the trial in alignment with the independent Data Monitoring Committee.

https://www.emdgroup.com/en/news/javelin-ovarian-100-21-12-2018.html

• ECOG PS 0 or 1	N		
 Mandatory archival tip 	ssue 1:1:1		n = ~951
Primary Endpoint:	PFS		
Secondary Endpoints:	Maintenance PFS, OS, ORR, duration of response, pCR, PROs, safety, PK		

- Patients with SD or better will be allowed to continue to maintenance
- Chemotherapy: Choice of Q3W carboplatin-paclitaxel OR carboplatin + weekly paclitaxel
- Maintenance avelumab up to 2 years

ORR, overall response rate; OS, overall survival, pCR, pathological complete response; PFS, progression-free survival, PK, pharmacokinetics;


PROs, patient-reported outcomes; SD, stable disease.

Clinicaltrials.gov. Accessed October 11, 2016.





JAVELIN Ovarian 200 Results



sitc

Avel. + PLD

(N=188)

134 (71.3)

3.7

(3.3; 5.1)

0.78

(0.587; 1.244)

 0.0301^{+}

PLD

(N=190)

125 (65.8)

3.5

(2.1; 4.0)



Clinical trials in ovarian cancer – AA + IO

Trial	Population	Arms	Status
IMaGYN050	Neo-adjuvant St III/IV ovarian, peritoneal, fallopian tube	 Bevacizumab + chemo + placebo Bevacizumab + chemo + atezolizumab 	Recruiting
ATALANTE	Recurrent, Pt-sensitive ovarian	 Bevacizumab + chemo + placebo → placebo Bevacizumab + chemo + atezolizumab → atezolizumab 	Recruiting
NRG-GY009	Recurrent, Pt-resistant ovarian	 PLD + atezolizumab PLD + atezolizumab + bevacizumab PLD + bevacizumab 	Scheduled interim monitoring





Clinical trials in ovarian cancer – PI + IO


Trial	Population	Arms	Status
JAVELIN Ovarian 100 PARP	Untreated St III/IV ovarian	 Chemo + avelumab → avelumab + talazoparib Chemo → talazoparib Chemo + bevacizumab → bevacizumab 	 Discontinued in 3/2019: Poor outcomes in JAVELIN ovarian 100 in unselected patients Approval of PARP inhibitor in frontline maintenance
ATHENA	St III/IV ovarian, peritoneal, fallopian tube – only previous treatment 1 st line Pt		Recruiting
ANITA	Recurrent ovarian, peritoneal, fallopian tube	 Chemo + placebo → Niraparib + placebo Chemo + atezolizumab → Niraparib + atezolizumab 	Recruiting
			ACCCC A HOPA



Clinical trials in ovarian cancer – PI + AA + IO

Trial	Population	Arms	Status
FIRST	Newly diagnosed ovarian	 Chemo + placebo ± bevacizumab → placebo ± bevacizumab Chemo + placebo ± bevacizumab → niraparib + placebo ± bevacizumab Chemo + anti-PD-1 ± bevacizumab → niraparib + anti-PD-1 ± bevacizumab 	Recruiting
ENGOT- ov46/DUO-O	Newly diagnosed ovarian	 Chemo + placebo + bevacizumab → bevacizumab + placebo Chemo + bevacizumab + durvalumab → bevacizumab + durvalumab + placebo Chemo + bevacizumab + durvalumab → bevacizumab + durvalumab + olaparib 	Recruiting
ENGOT-ov43	1 st line ovarian	 Pembrolizumab + olaparib ± bevacizumab Pembrolizumab + placebo ± bevacizumab Placebo ± bevacizumab 	Recruiting





Cervical cancer immunotherapy opportunities:

- Inhibit the tumor-induced immunosuppression
- Stimulate HPV-targeted immune response


Jun-Han, BioDrugs 2010. Piersma, Cancer Res 2007.





In development: Cell therapies in HPV-associated cancers

- TIL treatment of HPV+ cancers, ~half cervical cancer
- 28% ORR in cervical, 18% non-cervical






Break Through Designation TIL in recurrent cervical cancer

Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.

- 27 efficacy evaluable patients
- ORR was 44% (1 CR, 9 PR, 2 uPR)
- DCR was 89% at 3.5-month median study follow-up with 11/12 patients maintaining their response







Break Through Designation MSS/pMMR Endometrial Cancer-2nd line Pembrolizumab+Lenvatinib

- KN-146
- N=54
- 13 months follow up
- ORR 40%
- Toxicity is a concern? (>50%)
 - Can we find better less toxic alternative to Lenvatinib

Makkar et al, The Lancet Oncology, 2019





Immunotherapy in breast cancer shows promise in certain subtypes

• For ovarian and MSS-endometrial cancers, combinations seem to be the way to go

 Cervical cancer and HPV-associated cancers present unique treatment options





Case Studies





Case Study 1

 50 year old woman with history of abnormal pap smear with atypical glandular cells of endometrial origin in Jan. 2018 with no follow up then in July 2018, she presented with shortness of breath. Work up includind CT PE showed evidence of bilateral PE. At that time, she reported vaginal bleeding. CT abdomen/pelvis was c/w extensive pelvic adenopathy (largest 5.5 on left nd 4 cm on right), left adnexal mass and cervical mass extending to upper vagina and lower endometrium.

• What would be your next step:

- She underwent IR biopsy of the pelvic adenopathy
- Results: high grade adenocarcinoma, P53+, ER+, PAX8+, CDX2-, TTF1-, P16+
 - Endometrioid cell type
 - Mulerian origin
 - Cervical vs. endometrial
 - ?HPV status







• Treatment course

1. Neo-adjuvant chemoRT with weekly cisplatin

- Post-Tx PET/CT scan showed persistent disease with new para-aortic adenopathy
- 2. Next Step:
- 3. Chemotherapy: Carboplatin/Taxol
 - Could not be tolerated
- 4. Next step
 - Tumor for MMR status, genomic profiling
 - IHC: loss of PMS2/MLH1 expression
- 5. Next step



Case Study 1

- 5. Next step
 - A. Somatic vs. germline: MLH1 promoter methylation
 - **B.** Immunotherapy with PD1 inhibitor pembrolizumab
 - Major treatment response with resolution of adenopathy, decrease in size of adnexal masses and normalization of CA-125 (450s at start) then continued with stable disease (durable major partial response)
 - Still on treatment and currently received 12 cycles

6. Question: CA-125 is rising but CT scan stable, what would you do?







- 61 yr old woman with fatigue and vaginal bleeding. CT scan showed pelvic and retro-peritoneal adenopathy and 5-6cm pelvic mass in the lower uterine segment extending to the cervix. On exam friable 6-7 cm cervical mass extending to bilateral parametria and upper vagina was noted.
- Next step:
 - She underwent exam under anasthesia, biopsies, cystoscopy and proctoscopy
 - Results: moderately differentiated squamous cell carcinoma
 - Pelvic MRI and PET/CT scan: multiple hypermetabolic pulmonary nodules, large cervical mass, retroperitoneal/pelvic and inguinal adenopathy
- Next step





Case Study 2

- Primary chemotherapy: Regimen?
 - Cisplatin/Taxol/bevacizumab. Received 9 cycles
 - Initial response then disease progression with increased size of cervical mass and adenopathy
- Next step?
 - Immunotherapy with pembrolizumab?
- What test do you need?
 - PDL1 testing: what do you do at your site PDL1 or CPS
 - What is the difference?
 - CPS for her came back 25
- Started immunotherapy with pembrolizumab.
 - Stable disease, s/p 6 cycles thus far

